HABA LABORATORIES,INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,065 JPY | +1.98% |
|
+3.20% | -4.88% |
| 2023 | HABA Laboratories,Inc. Reports Earnings Results for the Full Year Ended March 31, 2023 | CI |
| 2021 | HABA Laboratories,Inc.(JASDAQ:4925) dropped from S&P Global BMI Index | CI |
Valuation
| Fiscal Period: März | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 30,800 | 27,417 | 17,584 | 17,225 | 8,172 | 8,811 |
| Enterprise Value (EV) 1 | 28,285 | 23,571 | 15,298 | 15,480 | 5,078 | 6,026 |
| P/E ratio | 19.3 x | 13.1 x | 13.7 x | 79.7 x | -30.4 x | -12.5 x |
| Yield | 0.38% | 0.57% | 0.86% | 0.88% | 1.85% | 1.72% |
| Capitalization / Revenue | 1.72 x | 1.42 x | 0.96 x | 1.2 x | 0.63 x | 0.73 x |
| EV / Revenue | 1.58 x | 1.22 x | 0.83 x | 1.08 x | 0.39 x | 0.5 x |
| EV / EBITDA | 9.38 x | 6.35 x | 5.82 x | 17.3 x | 13 x | -121 x |
| EV / FCF | 16.5 x | 17.7 x | -60.9 x | -31.5 x | 3.28 x | 45.8 x |
| FCF Yield | 6.07% | 5.64% | -1.64% | -3.18% | 30.5% | 2.18% |
| Price to Book | 3.09 x | 2.29 x | 1.47 x | 1.43 x | 0.7 x | 0.82 x |
| Nbr of stocks (in thousands) | 3,934 | 3,934 | 3,782 | 3,782 | 3,782 | 3,782 |
| Reference price 2 | 7,830 | 6,970 | 4,650 | 4,555 | 2,161 | 2,330 |
| Announcement Date | 18-06-18 | 19-06-17 | 20-06-30 | 21-06-21 | 22-06-20 | 23-06-19 |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: März | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 17,885 | 19,253 | 18,369 | 14,307 | 12,908 | 12,038 |
| EBITDA 1 | 3,016 | 3,711 | 2,628 | 896 | 391 | -50 |
| EBIT 1 | 2,400 | 3,095 | 1,998 | 227 | -317 | -609 |
| Operating Margin | 13.42% | 16.08% | 10.88% | 1.59% | -2.46% | -5.06% |
| Earnings before Tax (EBT) 1 | 2,379 | 3,072 | 1,927 | 283 | -267 | -548 |
| Net income 1 | 1,597 | 2,088 | 1,313 | 216 | -269 | -707 |
| Net margin | 8.93% | 10.85% | 7.15% | 1.51% | -2.08% | -5.87% |
| EPS 2 | 406.0 | 530.8 | 339.2 | 57.12 | -71.13 | -187.0 |
| Free Cash Flow 1 | 1,718 | 1,330 | -251 | -491.5 | 1,548 | 131.6 |
| FCF margin | 9.6% | 6.91% | -1.37% | -3.44% | 11.99% | 1.09% |
| FCF Conversion (EBITDA) | 56.95% | 35.85% | - | - | 395.78% | - |
| FCF Conversion (Net income) | 107.56% | 63.72% | - | - | - | - |
| Dividend per Share 2 | 30.00 | 40.00 | 40.00 | 40.00 | 40.00 | 40.00 |
| Announcement Date | 18-06-18 | 19-06-17 | 20-06-30 | 21-06-21 | 22-06-20 | 23-06-19 |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: März | 2020 S1 | 2021 S1 | 2022 S1 | 2022 Q3 | 2023 Q1 | 2023 S1 | 2023 Q3 | 2024 Q1 | 2024 S1 | 2024 Q3 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 9,532 | 6,653 | 5,984 | 3,574 | 2,787 | 5,652 | 3,083 | 2,569 | 5,527 | 3,109 |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | 1,480 | -320 | -568 | 63 | -212 | -346 | -421 | -290 | -464 | -109 |
| Operating Margin | 15.53% | -4.81% | -9.49% | 1.76% | -7.61% | -6.12% | -13.66% | -11.29% | -8.4% | -3.51% |
| Earnings before Tax (EBT) 1 | 1,446 | -300 | -517 | 47 | -198 | -304 | -409 | -293 | -468 | -172 |
| Net income 1 | 956 | -201 | -464 | -65 | -140 | -230 | -580 | -215 | -345 | -567 |
| Net margin | 10.03% | -3.02% | -7.75% | -1.82% | -5.02% | -4.07% | -18.81% | -8.37% | -6.24% | -18.24% |
| EPS 2 | 243.3 | -53.38 | -122.8 | -17.15 | -37.21 | -61.02 | -153.4 | -56.87 | -91.33 | -149.8 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 19-11-11 | 20-11-11 | 21-11-10 | 22-02-10 | 22-08-12 | 22-11-11 | 23-02-10 | 23-08-10 | 23-11-10 | 24-02-09 |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: März | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 2,515 | 3,846 | 2,286 | 1,745 | 3,094 | 2,785 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 1,718 | 1,330 | -251 | -492 | 1,548 | 132 |
| ROE (net income / shareholders' equity) | 17.3% | 19% | 11% | 1.8% | -2.27% | -6.31% |
| ROA (Net income/ Total Assets) | 10.4% | 12.2% | 7.44% | 0.82% | -1.2% | -2.51% |
| Assets 1 | 15,336 | 17,157 | 17,657 | 26,287 | 22,490 | 28,179 |
| Book Value Per Share 2 | 2,538 | 3,038 | 3,166 | 3,183 | 3,077 | 2,849 |
| Cash Flow per Share 2 | 1,282 | 1,506 | 1,382 | 1,498 | 1,494 | 1,274 |
| Capex 1 | 673 | 302 | 650 | 796 | 124 | 191 |
| Capex / Sales | 3.76% | 1.57% | 3.54% | 5.56% | 0.96% | 1.59% |
| Announcement Date | 18-06-18 | 19-06-17 | 20-06-30 | 21-06-21 | 22-06-20 | 23-06-19 |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -4.88% | 49.12M | |
| +18.31% | 20.69B | |
| 0.00% | 18.4B | |
| +9.50% | 11.56B | |
| -10.06% | 9.69B | |
| +16.41% | 7.66B | |
| +12.57% | 6.19B | |
| +3.02% | 4.62B | |
| -16.68% | 3.91B | |
| -7.04% | 3.69B |
- Stock Market
- Equities
- 4925 Stock
- Financials HABA Laboratories,Inc.